HC Wainwright Has Lowered Expectations for TuHURA Biosciences (NASDAQ:HURA) Stock Price

TuHURA Biosciences (NASDAQ:HURA) had its target price lowered by stock analysts at HC Wainwright from $13.00 to $12.00 in a research note issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 255.03% from the stock’s previous close. HC Wainwright also issued estimates for TuHURA Biosciences’ Q3 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.09) EPS, Q1 2027 earnings at ($0.09) EPS, Q1 2027 earnings at ($0.09) EPS and Q2 2027 earnings at ($0.09) EPS.

A number of other research analysts have also recently issued reports on the stock. Rodman & Renshaw assumed coverage on shares of TuHURA Biosciences in a report on Thursday, December 19th. They set a “buy” rating and a $11.00 price objective for the company. RODMAN&RENSHAW upgraded TuHURA Biosciences to a “strong-buy” rating in a research note on Thursday, December 19th.

TuHURA Biosciences Trading Down 0.6 %

Shares of NASDAQ:HURA opened at $3.38 on Thursday. The stock’s 50 day moving average price is $3.42. TuHURA Biosciences has a twelve month low of $1.80 and a twelve month high of $7.93.

Institutional Trading of TuHURA Biosciences

Several institutional investors have recently made changes to their positions in HURA. Accent Capital Management LLC purchased a new position in TuHURA Biosciences during the fourth quarter worth about $29,000. TT Capital Management LLC bought a new position in shares of TuHURA Biosciences during the 4th quarter worth approximately $41,000. Jefferies Financial Group Inc. purchased a new position in shares of TuHURA Biosciences in the 4th quarter worth approximately $54,000. Bank of America Corp DE purchased a new position in shares of TuHURA Biosciences in the 4th quarter worth approximately $59,000. Finally, Charles Schwab Investment Management Inc. bought a new position in shares of TuHURA Biosciences in the fourth quarter valued at approximately $61,000. Institutional investors own 0.62% of the company’s stock.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.